MORNINGSIDE VENTURES INVESTS IN THIRTY HOLDINGS

Thirty Holdings Limited completed a £25 million equity investment led by Morningside Ventures, a major investor in the global Life Science sector. The investment enables the Group to accelerate research and development. We are delighted to welcome Isaac Cheng to the...

A NEW NAME FOR A NEW ERA

Thirty Holdings Limited established following a corporate restructure. The Company trading name will be 30 Technology with the name derived from the molecular weight of nitric oxide (30). Edixomed Limited is now a wholly owned subsidiary of Thirty Holdings, focusing...

BREAKTHROUGH TECHNOLOGY

Breakthrough Technology to Prevent and Treat Antibiotic Resistant Infection New results announced at the recent Wounds UK conference and Eurobiofilms 2017 congress have provided the latest evidence that Edixomed, a UK biotechnology company, has developed a...

US AND EU PATENTS GRANTED

Edixomed Granted US and EU Patent Protection for Their Nitric Oxide Generating Treatment System Edixomed have been granted Intellectual Property protection for their nitric oxide generating treatment system in both the EU and USA. The priority date for the patents is...

ANTIMICROBIAL EFFECTIVENESS

Edixomed completes anti-microbial efficacy study An independent analysis performed by Perfectus Biomed and utilising the FDA stipulated AATCC Test Method 100-2004, indicates that the Company’s lead product has achieved the required bacterial and fungal reduction to...